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Abstract: Ciguatera Fish Poisoning (CFP) is the most frequently reported seafood-toxin 
illness in the world, and it causes substantial physical and functional impact. It produces a 
myriad of gastrointestinal, neurologic and/or cardiovascular symptoms which last days to Mar. Drugs 2008, 6  457
 
 
weeks, or even months. Although there are reports of symptom amelioration with some 
interventions (e.g. IV mannitol), the appropriate treatment for CFP remains unclear to many 
physicians. We review the literature on the treatments for CFP, including randomized 
controlled studies and anecdotal reports. The article is intended to clarify treatment options, 
and provide information about management and prevention of CFP, for emergency room 
physicians, poison control information providers, other health care providers, and patients.  
Keywords: ciguatera fish poisoning, ciguatoxin, harmful algal bloom (HAB), treatment, 
human health, marine toxins 
 
1. Introduction 
 
Ciguatera fish poisoning (CFP) is a foodborne illness affecting humans worldwide. Humans acquire 
this illness by eating reef fish containing the naturally occurring toxins, ciguatoxins. Multiple 
ciguatoxins have been identified, but in this paper ciguatoxins will be referred to collectively as 
“CTX.” CTX is derived from benthic dinoflagellates of the genus Gambierdiscus,  growing 
predominantly in association with macroalgae in coral reefs in tropical and subtropical climates. The 
toxin is transferred through the food web as the algae is consumed by herbivorous fish, which are 
consumed by carnivorous fish, which are in turn consumed by humans [1-5]. This review article 
describes the human health aspects of CFP, as well as prevention and treatment. It also provides 
information about public health management of CFP particularly within the United States of America. 
1.1. Epidemiology   
The frequency of CFP varies by region throughout the world. Table 1 summarizes various regional 
reports on the incidence and prevalence of CFP [6]. 
It is estimated that 10,000-50,000 people per year who live in or visit tropical and subtropical areas 
suffer from CFP [7,8], but the true incidence of CFP is difficult to ascertain due to under-reporting. It 
is believed that only 2-10% of CFP cases are reported to health authorities [5-7,9]. In Miami-Dade 
County (Florida), using the degree of under-reporting from a community outbreak of waterborne 
gastroenteritis as a guideline, it was suggested that for every reported case of CFP, between 10 and 100 
cases may go unreported [9].  
Under-reporting occurs in part because individuals with CFP often do not seek medical attention, 
particularly in locations where CFP is well-known to local residents. However, even if they do seek 
medical attention, health professionals may not recognize the disease or report it to health authorities. 
In one study [10], a classic case of CFP was presented to 36 physicians in South Florida, where CFP is 
endemic. While 68% of the physicians correctly diagnosed a classic case of CFP, only about 47% of 
the physicians knew that CFP was a reportable disease (i.e. required by law to be reported to the health 
department); only 17% of the physicians recommended mannitol therapy (see below). Another factor 
contributing to under-reporting is whether or not a given case is part of an outbreak; a study of CFP in Mar. Drugs 2008, 6  458
 
 
South Florida revealed that potential CFP cases were less likely to be reported or confirmed when a 
given case was a single illness, as compared to being part of an outbreak or cluster of CFP cases [11].  
Table 1. Reported Incidence and Prevalence of CFP. 
Geographic Region  Incidence/ 
10,000/year 
Data collection time 
period 
Reference 
 
Reunion Island  0.78  1986-1994  Quod 1996 [25] 
Queensland, Australia  3  1965-1984  Gillespie 1986 [4] 
Hawaii  0.3  1975-1981  Anderson 1983 [96] 
US Virgin Islands  7.6  1982  Morris 1982 [97] 
Guadeloupe 30  1984  Czernichow  1984  [98]   
South Pacific Region  970  1973-1983  Lewis 1986 [99] 
Marshall Islands  2,820  1982-1983  Lewis 1986 [99] 
French Polynesia  5,850  1979-1983  Lewis 1986 [99] 
Dade County, FL  5   1974-1976  Lawrence 1980 
Culebra, Puerto Rico  73.6-169.5  2005-2006  Luber, In prep [100]  
      
Geographic Region  Prevalence (%) Time  range  Citation 
 
St. Thomas (US Virgin Islands)  4.4  Annual (1980)  McMillan 1980 [101] 
Puerto Rico  7  Lifetime  Holt 1984 [102] 
Tahiti  8.45  Annual (1966)  Bagnis 1979 [16] 
Hao (Tuamotos)  43  Annual (1978)  Lewis 1986 [99] 
Polynesian Islands  70  Lifetime  Lewis 1986 [99] 
1.2. Pharmacology 
CTX is one of the most potent natural substances known. One of the ciguatoxins (P-CTX-1, found 
in the Pacific Ocean) poses a health risk at concentrations as low as 0.08 to 0.1 μg/kg [5], although 
CTX rarely accumulates in fish at levels that are lethal to humans [12]. CTX activates the voltage-
gated sodium channels in cell membranes, which increases sodium ion permeability and depolarizes 
the nerve cell. This depolarization of nerve cells is believed to cause the array of neurological signs 
associated with CFP [7,12-14].  
1.3. Symptoms and Course 
In the absence of a human biomarker to confirm CFP, the diagnosis of CFP is based on the clinical 
scenario and the patient’s recent fish-eating history. CFP is associated with gastrointestinal (GI), 
cardiovascular, neurological and neuropsychiatric symptoms and signs. The symptomatology has been 
addressed in considerable detail in numerous publications [5,12,15-20]. Table 2 summarizes the 
frequency of CFP symptoms in a variety of reports.  Mar. Drugs 2008, 6  459
 
 
Gastrointestinal symptoms and signs (e.g. vomiting, diarrhea, abdominal pain, nausea) develop 
within 6-24 hours of eating a reportedly good-tasting reef fish, and usually resolve spontaneously 
within 1-4 days. Cardiac symptoms and signs may also occur, generally only in the early stage of the 
disease process; cardiac signs may include hypotension and bradycardia, and may necessitate urgent 
medical care.  
The neurologic symptoms, which generally present within the first few days of illness, often 
become prominent after the GI symptoms, particularly in CFP from fish obtained in Caribbean waters. 
Neurologic symptoms vary among patients and include the following: paresthesias (numbness and 
tingling) in the extremities (feet and hands) and oral region, generalized pruritis (itching), myalgia 
(muscle pain), arthralgia (joint pain), and fatigue. A distinctive symptom reported by many patients is 
an alteration or “reversal” of hot/cold temperature perception, in which cold surfaces are perceived as 
hot to the patient, or produce dysesthesia (unpleasant, abnormal sensation). This temperature-related 
dysesthesia is considered characteristic of CFP, although not all patients report experiencing this 
symptom.  
Temperature-related dysesthesia has been reported not only in CFP but also in Neurotoxic Shellfish 
Poisoning (NSP), which is caused by human consumption of shellfish contaminated by a toxin known 
as brevetoxin; therefore, in potential CFP patients presenting with temperature dysesthesia, if there is a 
history of eating shellfish then the differential diagnosis of NSP should be considered.  
Of note, there is new research indicating that that brevetoxin can accumulate not only in shellfish, 
but also in muscles and viscera of fin-fish [21], posing a threat to marine mammals who consume them 
[22]. Although this suggests that theoretically, human consumption of brevetoxin-contaminated fin-
fish may place individuals at risk for NSP, there are no documented cases of NSP from eating fin-fish, 
and the relevant concentrations of brevetoxins in fish fillets consumed as meals have not been 
documented at this time. Therefore, clinical presentation of temperature-related dysesthesia is still 
considered distinctive of CFP (rather than NSP) when there is a recent history of consuming fin-fish 
(as opposed to shellfish). 
Neuropsychiatric symptoms in CFP may include anxiety [23], depression and subjectively reported 
memory loss [24]. More marked mental status changes such as hallucinations, giddiness [25], 
incoordination or ataxia [25,26], and coma [16] have been reported, but appear to be specific to CFP in 
Indian and Pacific Ocean regions. 
Regional differences in symptom patterns have been noted and may be attributable to the presence 
of different suites of CTX or toxin precursors in different geographic regions [27]. In the Caribbean, 
gastrointestinal symptoms and signs predominate in the acute phase (i.e. first 12 hours [9]), with 
subsequent prominence of neurologic, especially peripheral neurologic symptoms. In the Pacific, the 
neurological symptoms and signs predominate [12] and there have been reports, though uncommon, of 
more severe neurologic effects including coma [16]. In the Indian Ocean, CFP has also been associated 
with neurological and mental status alterations, with reports of hallucinations, giddiness, 
incoordination, loss of equilibrium, and depression [25]. Mar. Drugs 2008, 6  460 
 
 
Table 2. Reported Frequency (%) of Clinical Symptoms of Ciguatera at Time of Diagnosis 
   Region of Study 
Author 
Number of Cases 
 Oceans  Caribbean  Atlantic  Pacific  Indian 
Reported Symptoms   Friedman 
[23] 
Arena 
[24]  
Stinn 
[42] 
Frennette 
[103] 
Engleberg 
 [104] 
Escalona  
[105] 
Lawrence 
 [9] 
Bagnis  
[26] 
Schnorf  
[64] 
Chateau-
Degat 
[106]  
Gillespie 
[4] 
Bagnis 
[16] 
Quod  
[25] 
N=12 N=12  N=442 N=57  N=47  N=80 N=129  N=12,890  N=50 N=47  N=527  N=3009  N=167 
Gastrointestinal:                       
Diarrhea 67  75  79  77  81  83  76  73  50    64  71  49 
Vomiting   42  43  37  40  69  68  39      35  38  50 
Nausea 42      82    69    44  26    55  43  50 
Abdominal Pain  42  75  65  58  30  74    43  52    52  46  29 
Neurologic:                       
Extremity Paresthesia  67  100  81  79    36  71  89  72  93  64-71  89  82 
Circumoral 
Paresthesia 
58   70  79  38  38 54 88   91  66  89  82 
Temperature 
Dysesthesia 
58 92  64 77  23  48    87  94 34 76  88  65 
Myalgia 67  75  79  75  34  56  86  85  56  80  83  82  38 
Arthralgia 42  83  79  75  34  60    86  62  80  79  86  29 
Pruritis 67  67  77    66  45  48  44  42    76  45  5 
Headache       56  45  39  47  60  50    62  59  25 
Vertigo 25  58  50     33  47    62    45  42   
Weakness (Asthenia)  92  100    84    65  30  60  80      60  70 
Dental Pain/Feeling 
like teeth are loose or 
falling out 
33   32  23  13  11    21     37  25   
Dysuria 8  33  25          13  26    22  19   
Chills/Sweating        36   24  60    49  59   Mar. Drugs 2008, 6  461 
 
 
Table 2. Cont. 
 
Neuropsychiatric:                       
Hallucinations 8  17                  <5  16 
Depression 25  17                   16 
Memory/concentration
problems 
17 58                      
Multi-tasking 
problems 
25                     
Giddiness              29          30 
Cardiovascular:                       
Arrhythmia 33                       
Hypertension              12  12         
Bradycardia              16  16         
Notes: Blank cells indicate that data on that symptom were not reported in the study referenced. 
The table does not provide relative risk data, i.e. it does not provide comparative information on symptom frequency in an unexposed population.  
            Table modified from Stinn et al., 2000; Arena et al., 2004 
 
 
Table 3. Foods and behaviors associated with symptom recurrence. 
Alcohol [4,6,27,74]  
Nuts [6,8]  
Caffeine [6]  
Pork [8]  
Chicken [4,8] 
Any kind of fish [4,6,27] 
Physical activity/exertion [74]  Mar. Drugs 2008, 6  462
 
 
CFP is rarely fatal. However, death may occur in severe cases due to severe dehydration, 
cardiovascular shock during the initial illness period, or respiratory failure resulting from paralysis of 
the respiratory musculature [17,28], especially in areas where ventilatory support and emergency 
medical care are unavailable. Eating fish organs or viscera (such as the head, liver or gonads) is 
associated with greater symptom severity than eating only the fillet, as CTX is present in greater 
concentrations in such organs [29][24].  
1.4. Chronicity 
After the initial or acute illness, feelings of weakness generally last a few days to several weeks. 
Some patients experience chronic symptoms lasting weeks to months, in particular peripheral 
neurologic symptoms such as paresthesias in the extremities, pruritis, and neuropsychiatric symptoms 
such as malaise, depression, generalized fatigue, headaches [1,14,24,29-34].  
In a small longitudinal study that assessed chronicity of symptoms in 12 CFP patients, there were 
no longer differences between patients and healthy control subjects on measures of neurotoxicity (e.g. 
paresthesias, headache, muscle weakness) or emotional symptomatology 6 months after initial illness 
[23]. However, the CFP cases in that study were intoxicated primarily by fish from Caribbean waters. 
Caribbean CTX is believed to be less acutely potent than Pacific or Indian Ocean CTX [12], and toxin 
potency or the regional mixture of toxins may mediate symptom chronicity.  
Although rare, there are reports of neurologic symptoms, presumed to be associated with CFP, 
lasting for years in some patients [9,26,32]. However, such protracted complaints should be studied 
further to address potentially confounding psychiatric and medical explanations for them. In individual 
patients whose  symptoms last for more than a year, explanations other than CFP should be 
investigated. 
1.5. Symptom recurrence and sensitization 
There are reports of sensitization to ciguatoxins in CFP patients; that is, individuals who previously 
suffered from CFP have been reported to experience recurrence of CFP symptoms after eating a 
potentially ciguateric fish that did not produce symptoms in other individuals [4,35]. Also, anecdotal 
reports indicate that some patients experience recurrence of neurologic CFP symptoms upon 
consuming alcohol, any type of fish, and certain other foods (See Table 3), even years after the initial 
exposure [26,36]. When this occurs many years after exposure, however, alternative etiologies for 
symptoms should be ruled out, given that apparent CFP symptoms and signs may actually be 
indicators of other severe pathology [37]. Such reports of recurrence have not been noted for cardiac or 
gastrointestinal symptoms. 
One theory to explain the recurrence of neurologic symptoms is that ingested CTX may be stored in 
a person’s adipose tissue, and that any activity involving increased lipid metabolism may result in 
ciguatoxins re-entering the blood stream, with subsequent re-emergence of CFP symptoms [12]. 
Alternatively, symptom recurrence may be related to immunologically mediated sensitization to CTX 
after initial exposure [37,38].  Mar. Drugs 2008, 6  463
 
 
1.6. Diagnosis  
There are currently no reliable biomarkers that can be used to confirm exposure to CTX in humans, 
although studies using animals [39-41] indicate that detection of CTX in human blood or serum may 
be possible in the near future.  
At present, therefore, CFP diagnosis is based on the presenting symptoms and time course, the 
history of having eaten a reef fish (as opposed to shellfish as in Neurotoxic Shellfish Poisoning), and 
importantly, the exclusion of other diagnoses that could account for the symptoms. CFP has symptoms 
in common with Paralytic and Neurotoxic Shellfish Poisonings, scombroid and pufferfish toxicity, 
botulism, enterovirus 71, and bacteremia [7,37], as well as organophosphate pesticide poisoning, 
eosinophilic meningitis, multiple sclerosis, and other neurologic conditions.  
The current gold standard diagnosis of CFP would include confirmation of CTX in the consumed 
fish by appropriate laboratory methods (see Detection in Fish, below). Also, multiple individuals 
consuming the same fish, with all individuals experiencing signs, symptoms and time course consistent 
with CFP, strongly supports the CFP diagnosis [42].  
1.7. Detection in Fish  
Although diagnostic methods for detecting CTX in human specimens are still under development, 
methods for detecting the toxins in samples of the implicated fish have been developed, and the results 
have been used to support clinical diagnoses of CFP in the United States, Caribbean and South Pacific. 
Within the USA, laboratories of the Food and Drug Administration (FDA) perform CTX analyses on 
fish to assist in the CFP diagnosis of patients. Remnants of consumed fish can be submitted to the 
FDA for analysis, (see Recommendations, below). However, because the results of such analyses are 
generally not immediately available to the physician at the time of the patient’s initial presentation and 
examination, initial care of the patient must proceed based on symptom progression, recent fish-eating 
history, and exclusion of alternative diagnoses or explanations.  
The FDA fish testing procedure is a two-tiered protocol involving: 1) in vitro assay, i.e. a high-
throughput screen for toxicity consistent with ciguatoxin’s mode of action; and 2) an analytical 
chemistry technique known as liquid chromatography-mass spectrometry (LC-MS).  
In the first tier, suspect fish specimens are screened for the specific effects of CTX. Specifically, 
fish specimens are screened for voltage-gated sodium channel–specific activating effects on cell 
membranes. The screening procedure used is the in vitro mouse neuroblastoma (N2a) cell assay 
(American Type Culture Collection CCL-131), using a ouabain-veratridine dependent method [43,44]. 
Through appropriate experimental design, this screening method can detect effects of algal toxins on 
sodium channels in cell membranes, can discriminate between effects of toxins that activate (e.g. 
brevetoxins, ciguatoxins) versus block (e.g. tetrodotoxins, saxitoxins) voltage-gated sodium channels, 
and can discriminate between the effects of sodium channel specific toxins and toxins with other 
modes of action. However, this screening procedure does not identify specifically the sodium channel 
active agent present in the fish tissue. Therefore, in the second tier, fish samples that test positive for 
sodium channel specific toxicity are subjected to LC-MS, to confirm the molecular presence of CTX in 
the fish tissue. Multiple Reaction Monitoring (MRM) is used to selectively detect product ions from Mar. Drugs 2008, 6  464
 
 
ciguatoxin precursor ions. This method provides a high level of specificity for detecting CTX in fish 
[45].  
Of note, alternative methods for CTX detection in fish tissues with equivalent or lesser sensitivity 
and specificity have been reported, and include receptor binding assay which is also sodium channel 
specific and is considered to be sensitive [46-51]; LC-MS methods [48,52,53]; and a host of other less 
frequently employed assay systems (see review by Lewis, 2004 [54]).  
While the fish analysis procedures described here are performed generally in specially equipped 
laboratories by trained professionals, attempts have been made to develop simpler procedures that are 
cost-effective and can be used to detect ciguatera toxins on a routine basis by fishermen, fish vendors 
or consumers. However, developing such simplified techniques involves substantial challenges, 
including the low levels of CTX present in ciguateric fish (<0.05 parts per billion for one common type 
of CTX molecule), multiple structural toxin forms present within a single fish, and the small quantities 
of ciguatera compounds available for research [27]. A membrane immunobead assay was developed in 
Hawaii [55] as a simplified ciguatoxin detection procedure, but available studies evaluating the 
immunobead procedure on samples from the Caribbean and from Hong Kong revealed false negative 
detection rates ranging from 50-82%, and false positive rates ranging from 33-44% [56,57]. To date, 
there is no commercially available fish-testing product that has been demonstrated by independent 
investigation to provide ciguatoxin detection with adequate accuracy [56,57].  
Access to CTX for research purposes is a significant challenge. Purified CTX from the Caribbean 
and Pacific are not widely available for laboratory experimentation due to the low amount of toxin 
present in fish, although a few specialized laboratories have purified sufficient quantities for research 
and outbreak investigations [e.g. Murata et al. 1989, 1990 [59,60]; Crouch et al. 1995 [61]; Vernoux et 
al. 1997 [62]; Lewis et al, 1991 [63]; Hamilton et al., 2002] [53].  
2. Treatments 
Over the years, a myriad of treatments, mostly responding to CFP symptoms, have been tried. 
However, there have been few well-designed randomized controlled trials investigating the 
effectiveness of specific treatments for CFP. Some of the research design challenges and problems 
include the relative infrequency and irregularity of CFP’s occurrence, lack of resources for conducting 
scientific treatment investigations in those places where it occurs with greater frequency, the inability 
to confirm the diagnosis of CFP using a human biological assay, small numbers of patients (which is 
particularly problematic when attempting to compare subgroups of participants), variability among 
study participants in time to treatment, and potential differences between Pacific, Indian Ocean, and 
Caribbean toxins and their effects. In addition, in the CFP literature, unless fish testing was available, 
it is generally unknown if the case reports and even clinical trials of CFP treatments were treating 
actual cases of CFP.  
2.1. Mannitol 
Intravenous (IV) mannitol infusion is the most studied therapy for CFP, and the only therapy 
evaluated by randomized blinded clinical trials [64,65]. IV mannitol is administered at 0.5 to 1.0 g/kg 
body weight over a 30-45 minute period. It is suggested that it be given within 48-72 hours of 
ingestion of toxic fish [66,67], although beneficial effects have been observed even up to several Mar. Drugs 2008, 6  465
 
 
weeks after intoxication [32,68]. The effect of mannitol infusion is thought to be mediated by the 
osmotic reduction of neuronal edema [1]. Also, mannitol may act as a scavenger of free radicals 
generated by the CTX molecule, and may reduce the action of CTX at sodium and/or potassium 
channels [69]. Nicholson and Lewis note that hazards of mannitol’s clinical use include loss of further 
fluids in patients suffering from acute diarrhea and vomiting, and that patients experiencing 
bradycardia and hypotension are at higher risk of cardiac failure if infused with high doses of mannitol 
[12]. Lewis and King [70] indicated that mannitol should not be administered until the patient is 
adequately rehydrated. Mannitol therapy has been recommended for two primary goals: Reduction of 
acute symptoms (especially neurologic) and possible prevention of chronic neurologic symptoms.  
Early descriptive reports on the use of IV mannitol suggested that it provided significant, rapid 
improvement and even resolution of acute CFP signs and symptoms. Also, based on the anecdotal 
reports that individuals treated with IV mannitol appeared to show reduced likelihood of returning for 
additional medical care, it was suggested that IV mannitol may even prevent the development of 
chronic CFP symptoms [32]. Palafox et al. [67] described 24 cases, 17 of whom experienced complete 
resolution of CFP symptoms within 48 hours of infusion, including two cases of coma and one case of 
shock who improved within minutes of infusion. They suggested that treatment with IV mannitol was 
associated with shortened time of significant morbidity and shortened hospital stays, based on their 
clinical experience. Another early report [71] examined 12 CFP cases, and indicated that IV mannitol 
was generally effective at alleviating symptoms when administered within several days of fish 
ingestion. Notably, in this report, one case showed complete recovery by 24 hours after ingestion 
without any treatment.  
 Blythe  et al. [68] provided a descriptive report on the experience of local South Florida 
practitioners using IV mannitol to treat patients with acute and chronic CFP symptoms. The report 
described 70 CFP cases treated with IV mannitol; the mean time from exposure to clinical presentation 
was 11.5 days (SD=44.5; range of 0.3 to 365 days). The study indicated that 29 of the 32 (91%) 
patients who received mannitol within 48 hours of presumed exposure experienced complete reversal 
of symptoms. In addition, IV mannitol was associated with moderate reduction, and in some patients 
complete resolution, of symptoms if given from 3-14 days after exposure; there was also a reported 
benefit when administered up to 70 days after exposure. Multiple treatments (e.g., up to four additional 
infusions) were necessary in five individuals. The authors reported that there were no adverse effects 
of mannitol treatment. Although 37 non-mannitol patients were included in the case series, analysis 
comparing symptom outcome between mannitol and non-mannitol treated patients was not reported, 
and there was no randomization or blinding employed as part of the study design, so it cannot be ruled 
out that patient or interviewer expectations, rather than the mannitol itself, accounted for all or part of 
the reported benefit in patients who received mannitol.  
A study by Bagnis et al. [65] randomized 63 CFP patients in French Polynesia to one of two 
treatment groups: IV mannitol infusion (n=34), or “standard” treatment (n=29) which included 
intravenous infusion of glucose, Vitamin B and calcium gluconate. Results indicated a statistically 
significant, greater reduction in symptomatology in the mannitol group compared to the standard 
treatment group. 
Schnorf et al. [64] conducted a double-blind, randomized study of mannitol treatment. Fifty patients 
were included in the study and were randomized to either mannitol treatment (n=25) or normal saline Mar. Drugs 2008, 6  466
 
 
infusion (n=25). Results indicated that both treatments were associated with clinical improvement and 
to a similar degree, and mannitol was not superior to saline. However, 25% of the mannitol group 
received their mannitol between 69 hours and 672 hours (28 days) after symptom onset, which is 
generally beyond the 48-72 hour period recommended by other reports [32,66,68], and which may 
have obscured the identification of benefits in patients who received it early on. The authors then 
compared outcome of patients receiving mannitol within 24 hours to those receiving it after 24 hours, 
and found no difference. However this subpopulation analysis suffered from small sample size. In 
addition, by truncating the group at 24 hours post symptom onset rather than 48-72 hours (which has 
been associated with mannitol benefit [32,66,68]), true difference in benefits may have been diluted in 
the comparison. Also, as is common in CFP treatment studies, the results may have been confounded 
by potential CFP misdiagnoses among study participants, since the diagnosis of CFP cannot be 
confirmed by any tests using human fluid or tissue samples, and since the study did not employ fish 
testing to confirm CTX in remnants of fish consumed by patients.  
2.2. Symptomatic and Supportive Treatments 
With acute CFP, support of any depressed vital functions is of utmost importance [70], and 
supportive therapies may be necessary for controlling fluid and electrolyte balance [27]. As in any 
acute poisoning, IV fluid resuscitation with large volumes of isotonic fluids may be necessary for 
patients in shock, with the addition of an IV pressor infusion if needed after volume repletion. 
Symptomatic bradycardia may require IV atropine dosing as needed (0.5 mg every 5 minutes to 
maintain a heart rate goal of 60 beats per minute, with no maximum total dosage limit) and/or 
temporary cardiac pacing. Rarely, critically ill CFP patients may require endotracheal intubation and 
mechanical ventilation for either airway protection if comatose or for respiratory failure. The prognosis 
for full recovery of critically ill patients is excellent with intensive care treatment when needed. Also, 
patients seen within the first few hours after ingestion of toxic fish may benefit from treatment with 
oral activated charcoal to prevent further absorption of toxin from the gut, although ongoing severe 
vomiting and diarrhea may prevent this [7].  
Various medical treatments for other CFP symptoms have been tried, but with variable success [72] 
and without randomized controlled trials to establish their effectiveness for this purpose. For instance, 
fluoxetine has been used for chronic fatigue [73]; amitriptyline for paresthesias, pruritis and headaches 
[74], [75]; and paracetemol (acetaminophen) and nifedipine for headaches [20,73]. Gabapentin has 
been used to treat pain [76] but caution is warranted in prescribing medications with addiction 
potential, given that there are no randomized controlled trials examining their safety and effectiveness 
for CFP, that patients’ complaints may last for months, and that chronic complaints may be 
confounded with psychiatric or other medical causes. It has been recommended that opiates and 
barbiturates be avoided since they may lead to hypotension, and because opiates may interact with 
maitotoxin, a natural marine toxin that may also be present in ciguatoxic fish [6].  
There is also a variety of traditional herbal medicines and remedies that have been used to treat 
ciguatera. For instance, 64 different plant species have been reportedly used in the Western Pacific 
[77], and extracts of Argusia argentea leaves or Davalliea sp. have been reported in New Caledonia 
[33]. However, there is no scientific evidence demonstrating that these remedies are safe or effective in 
treating CFP [12].  Mar. Drugs 2008, 6  467
 
 
2.3. Food and Dehydration Avoidance 
Frequent anecdotal reports to physicians and investigators indicate that after experiencing CFP, 
ingesting alcohol [4,6,26,27,74] and any kind of fish [4,6,26,27,35] can cause an augmentation or 
relapse of symptoms. Ingesting caffeine [6], nuts [6,8], chicken [4,8] and pork [8], or experiencing 
physical over-exertion or dehydration[74] have also been associated with symptom recurrence or 
augmentation. Therefore, patients are advised to avoid behaviors or activities that cause dehydration, 
and to avoid such foods (Table 3) for 3-6 months after intoxication or until all CFP-related symptoms 
have resolved. However, controlled investigations of the incidence of symptom recurrence as well as 
the effectiveness of specific food and activity avoidance measures have not been conducted, and any 
beneficial impact may vary among individuals.  
 
3. Prevention 
 
CFP is difficult to prevent because CTX in fish is odorless and tasteless, and toxic fish cannot be 
identified by appearance or behavior. CFP occurrences are not attributable to inadequate food 
handling, storage, preparation, or procurement methods for the contaminated fish. CTX is heat-stable, 
and therefore, cooking, boiling, freezing, baking or frying does not eliminate or destroy the toxin from 
the fish tissue [28]. Person-to-person transmission of CFP is exceedingly rare, but there are reports of 
transmission of GI symptoms from an acutely ill mother across the placenta to the fetus/newborn [6] 
and to a nursing infant [78], and of transient genital paresthesias in sexual partners of those with acute 
CFP [79].  
3.1. Avoiding Ciguateric Fish 
Prevention of CFP relies on the individual’s avoidance of fish that have a greater likelihood of 
ciguatoxicity. Local residents in endemic areas often report being aware of specific reefs and/or 
seasons to avoid when fishing. Local residents also report a variety of simple home tests to detect toxic 
fish, but none of these are scientifically validated.  
Intoxication is associated with consumption of large reef fish, and greater illness severity is 
associated with eating the fish viscera and larger portions [70]. Thus, people are advised to avoid 
eating the viscera of reef fish. It is also advisable to avoid consuming large predatory reef fish from 
areas known to be associated with CFP. With regard to fish size, avoidance of fish in excess of 3 
kilograms (approximately 6.6 pounds) [37], or even more conservatively, avoidance of fish in excess 
of 1.35 kilograms (approximately 3 pounds) [80] has been recommended. It has also been proposed 
that eating small portions (i.e. <50 grams or < 0.11 pounds) of different fish is safer than eating larger 
portions of any individual fish that might be associated with CFP [27,70].  
Table 4 provides a list of commonly ciguatoxic fish to avoid [4,32,52,81-84] , although any large 
coral reef fish has the potential to be ciguatoxic. Of note, recent reports [85] suggest that CFP may be 
associated not only with coral reefs, but also with oil rigs and other artificial reefs. 
In laboratory studies, fish that ingested ciguatoxic barracuda or freeze-dried cells of Gambierdiscus 
toxicus (i.e. the ciguatoxin-producing dinoflagellate) displayed skin color variation, inactivity, erratic 
swimming, and even death above certain dosages [86,87][74,75]. However, toxic fish in the field Mar. Drugs 2008, 6  468
 
 
generally do not appear to be harmed by CTX accumulated in their tissue; there is no reliable method 
of detecting ciguatoxicity in fish in the field based on their appearance or behavior.  
 
Table 4. Fish avoidance recommendations. 
 
Some Common Ciguatoxic Fish [4,32,52,81-84] 
 
Moray eel  
Barracuda 
Grouper 
Kingfish 
Jacks 
Snapper 
Surgeonfish 
Parrot fish 
Wrasses 
Hogfish 
Narrow barred Spanish mackerel 
Coral trout 
Flowery cod 
Red emperor 
 
The following are also associated with CFP 
 
Eating fish viscera or roe [29,70]  
Large, predatory reef fish* [37,70,80] 
Reef fish from areas known to be associated with CFP occurrence [70]  
Note that eating small portions (i.e. <50 grams or <0.11 pounds) of different fish may be 
safer [27] than eating larger portions (i.e. >200 grams) of any one potentially ciguatoxic 
fish [70]. 
* Lange et al., 1987 cites a recommendation to not eat fish larger than 1.35-2.25 kg (3-5 
pounds), whereas Ting and Brown (2001) recommend not eating fish larger than 3 kg 
(6.6 pounds). 
3.2. Surveillance and Reporting 
CFP is reportable to the health authorities in various states in the USA. For example, in the state of 
Florida, licensed physicians, chiropractors, naturopathy practitioners, and veterinarians are required by 
law to report suspected cases of CFP to the Department of Health (DOH) (Section 381.0031(1,2), 
Florida Statutes). Suspected cases are then investigated by public health officials and confirmed cases 
are recorded in the state’s registry of reportable/notifiable diseases. Investigation of cases includes a Mar. Drugs 2008, 6  469
 
 
telephone or face to face interview to gather case details, collection of remnants of the consumed fish 
for shipment for analysis at the FDA, and collection of medical and laboratory data needed to confirm 
the diagnosis and aid in surveillance. Determining the source of the fish purchased or place of capture 
is important in preventing additional cases that may occur when a large, recreationally caught fish is 
shared or when a wholesaler may have shipped toxic fish to other areas for resale. 
The Florida DOH also maintains a Food and Waterborne Disease Surveillance Program with a 
website providing information on CFP and other food borne diseases. This program contains a network 
of regional epidemiologists which coordinate with county health departments, the Florida Poison 
Information Center (FPIC), emergency departments and other health care providers to facilitate case 
investigation, reporting and public health education (www.myfloridaeh.com).  
The Florida Poison Information Center- Miami (FPIC-M) maintains a toll-free Aquatic Toxins 
Hotline which is available 24 hour/day (888-232-8635; from outside of the US but not toll-free: 305-
585-5250). The FPIC-M collects information on CFP occurrences and provides a summary of this data 
to the Florida Department of Health (DOH). The Florida DOH uses this information to augment 
surveillance of CFP and other marine and freshwater toxin illnesses for the Florida DOH and the 
Centers for Disease Control and Prevention. The FPIC-M also provides diagnostic, treatment, and 
educational information to callers from any location.  
In the USA, the FDA' s Center for Food Safety and Nutrition (CFSAN) conducts research on CFP 
and collaborates with academic and government counterparts, as part of its mission to protect and 
advance public health. The FDA has developed methods to screen and confirm the ciguatoxicity of 
CFP-implicated fish remnants, and collects data on  ciguatoxic fish species, toxin concentrations 
associated with human illness, and potential biomarkers of CFP in human body fluids. Therefore, 
submitting fish remnants to the FDA for CTX analysis contributes data essential for 
improving estimates of the true incidence of CFP, and for developing regulatory guidelines to reduce 
the incidence. For patients whose fish remnants are submitted to the FDA, current research efforts 
include the collection of patients’ blood and urine samples, in order to contribute to the development 
of a human biomarker of CFP, to assist in clinical diagnosis.  
Of note, in the USA, the National Oceanic and Atmospheric Administration (NOAA) Centers for 
Coastal Ocean Sciences (NCCOS) also conducts research on ciguatoxicity of fish as part of its mission 
to provide scientific information that addresses society’s environmental, economic and social goals, 
and promotes the health of the ecosystem and natural resources.  
3.3. Education and Outreach 
Community outreach and education on CFP are needed, given the under- and misdiagnosis, as well 
as under-reporting of it [88-93]. Primary prevention of CFP relies heavily on providing education 
about CFP and the fish associated with it to consumers, especially those most susceptible to CFP, such 
as recreational and subsistence fishermen and the communities that they serve. Additionally, 
identifying local reefs with a high density of ciguatoxic organisms and/or fish, and communicating this 
to fishermen via posting and other announcements is important, to help prevent ciguatoxic fish from 
entering the fish market.  
A number of health departments, other government agencies, researchers and grassroots groups 
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concerning various aspects of CFP. An example of high quality information is the information 
provided by the Florida Department of Health Aquatic Toxins Program which maintains a website 
with downloadable materials for a range of target audiences on CFP and other marine and freshwater 
toxin diseases (Figure 1) (http://www.doh.state.fl.us/environment/community/aquatic/index.html).  
As noted above, the FPIC-M maintains a toll free 24-hour hotline with information on CFP, and 
provides the opportunity to speak directly to a trained Poison Information Specialist [93].  
 
Figure 1. Example of outreach and educational materials developed for CFP 
(http://www.doh.state.fl.us/environment/community/aquatic/index.html); this Florida 
poster is targeted at fishers (W.B. Stephan MPH, Health Educator, FPIC-M) 
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4. Future Directions 
 
A number of future developments may help reduce the occurrence and impact of CFP in humans. 
First, to improve assessments of the true incidence of CFP, it is important to increase awareness and 
reporting of CFP occurrences to local health departments. Making CFP a “reportable” or “notifiable” 
disease in as many states as possible, even states where ciguatoxic fish are not typically caught, would 
increase awareness of the disease and facilitate better estimates of incidence; this is especially 
important given that ciguatoxic fish may be shipped to, resold, and ultimately consumed in a state 
other than the state where it was originally caught. Also, obtaining professional validation of the 
ciguatoxicity of suspect fish remnants is important for improving assessments of the true incidence of 
CFP.  
At the point of fish sale, or when consuming a pre-cut or pre-packaged portion or a prepared fish 
meal (e.g., a fish stew), individuals may not know the geographic origin, size or type of fish they 
purchase either for resale or for consumption. Therefore, tagging and tracking the geographic origin 
(including latitude and longitude data), size and type of fish, and making such information available to 
vendors and consumers may improve their ability to avoid ciguatoxic fish. Alternatively, bans may be 
placed on the capture or trade of certain fish species or fish from certain locations, or on coral reef fish 
over a certain size [27,42]. Posting announcements to fishers indicating which reefs are associated with 
known ciguatoxic fish may help to reduce CFP occurrences.  
One of the most important aspects of future management of CFP is the development of simple, cost-
effective methods of detecting ciguatera toxins in fish, which can be used by fishers, vendors and 
consumers, and which can provide satisfactory levels of accuracy. Research involving antibodies and 
reagents to synthesized CTX shows considerable promise for the future [94]. In humans, the 
development of methods to confirm exposure to CTX in affected individuals will assist not only in the 
diagnostic process, but in the validity of clinical trials investigating treatments for individuals with a 
presumed CFP diagnosis. 
With regard to treatment, one future direction pertains to brevenal, a recently discovered antagonist 
to brevetoxins (the toxins associated with the dinoflagellate, Karenia brevis, or the Florida red tide). 
Brevenal has been patented for possible use in brevetoxicosis in animals and humans. Due to the 
structural and physiologic similarity of brevetoxins and ciguatoxins, in the future, it is possible that 
brevenal (and the synthetic beta naphthoyl brevetoxin) may be used as a treatment for acute CFP in 
humans (Abraham et al., 2005 [95]; personal communication, LEF and Dr Daniel Baden, UNC 
Wilmington, NC).  More generally, future randomized, double-blinded controlled studies are needed to 
provide additional evidence to support or negate specific treatments for CFP, and to determine the best 
timing of treatment in the course of the illness.  
5. Recommendations 
Based upon available evidence and anecdotal experience, the authors recommend the following “best 
practice” guidelines for CFP clinicians: 
1. Use of IV mannitol: If a patient meets the criteria for a diagnosis of CFP, consumed the 
implicated species within the past 48-72 hours, and there are no contra-indications to its use, then 
treatment with IV mannitol is recommended. Repeat treatments may be necessary if symptoms return. Mar. Drugs 2008, 6  472
 
 
After 72 hours, IV mannitol treatment may be considered on a case by case basis, though it is not 
routinely recommended. Prior to treatment, as part of the process of informing patients about treatment 
options, patients should be informed about the inconsistency of research findings on the effectiveness 
of IV mannitol for CFP, the limitations of knowledge about its effects, as well as the fact that 
insurance will often not pay for this treatment. In all cases, the decision to proceed with mannitol 
treatment should be based upon the risk-benefit analysis, discussing such risks and benefits with the 
patient, and ultimately, the personal preference of the patient after being informed that it may not 
work.  
2. Supportive and symptomatic medical treatments: Supportive and symptomatic medical 
treatments for CFP symptoms should be determined on a case by case basis, according to the patient’s 
health situation, with the caveat that there are no randomized controlled studies investigating the 
effectiveness of any medical treatments other than mannitol for CFP. Caution is warranted in the use 
of medications with addictive potential for treating CFP symptoms, especially given the lack of 
research evidence supporting the safety or effectiveness of such medications for that purpose. 
3. For patients with chronic complaints that are not clearly caused by CFP, it is recommended that 
they receive a full evaluation by a neurologist, internist, and psychologist and/or psychiatrist, who can 
provide joint input on the diagnosis and a recommended plan of care.  
4. For patients with chronic complaints that do appear to be caused by CFP, based on experience at 
a local South Florida care center, patients may benefit from a low dose of selective serotonin reuptake 
inhibitor (SSRI), as well as a combination of assessment and care including a physical/occupational 
therapist, psychologist, and group psychotherapy sessions and/or family counseling, as needed, on a 
case by case basis.  
5. Fish avoidance: Avoidance of fish reported to be associated with CFP, as well as any large reef 
fish, large fish portions, head and viscera (e.g. liver, gonads), and fish obtained from regions known to 
be associated with CFP, is recommended (Table 4).  
6. Avoiding symptom recurrence: Avoidance of dehydration and certain foods is recommended for 
3-6 months after initial CFP intoxication or until the patient is symptom-free (Table 3). As an 
alternative to food and alcohol avoidance, patients may opt to try certain of the listed items but should 
be advised to do so cautiously and watch for recurrent symptoms. These recommendations are made 
with the following caveats: a) This is based on anecdotal reports; b) There are no empirical studies 
verifying the utility of such interventions, and c) This may not be helpful to all CFP patients.  
7. Report CFP: CFP should be reported to state or local health authorities. In some states (e.g. 
Florida), licensed physicians, laboratories and certain other practitioners are required by law to report 
suspected cases of CFP. Also, the Aquatic Toxins Hotline of the Florida Poison Information Center in 
Miami is a 24-hour resource available to people nationwide (888-232-8635; from outside of the US but 
not toll-free: 305-585-5250).  
8. Submit fish and clinical samples for testing: Upon determining that a patient has an illness caused 
by seafood consumption, physicians are encouraged to record time of meal consumption, amount of 
time between meal consumption and symptom onset, and obtain a detailed profile of patient 
symptoms. Physicians, other health care providers, or public health officials should also request from 
patients remnants of the fish that was actually consumed. Obtaining related information about the fish Mar. Drugs 2008, 6  473
 
 
such as the kind of fish (e.g. grouper, snapper, amberjack, etc.), where it was purchased or caught, and 
other people consuming the same fish (symptomatic or not) is also helpful.  
In the USA, implicated remnants of the consumed fish and the case-related information should be 
sent to the FDA laboratory for analysis of ciguatoxicity by public health authorities or poison control 
centers responding to the report, or by the Emergency Department physicians. In addition, in cases 
where fish remnants are being submitted for analysis, clinical samples of the patient's urine and whole 
blood, taken as close as possible to the time of symptom onset, may be solicited for submission to the 
FDA. For instructions on submitting fish and clinical samples, the FDA contact person is Ray Granade 
(hudson.granade@fda.hhs.gov), phone: (251) 690-3379.  
9. Randomized clinical trials of sufficient size are needed to document the occurrence of CFP, and 
the efficacy of IV mannitol and other common treatments. 
10. Creation of messages is recommended, to inform the public, fishermen, fish vendors, and 
restaurants about where to obtain good information on ciguatera. 
11. Educational modules targeted at medical students, emergency department personnel, poison 
information center personnel, and other health care providers should be developed and implemented.  
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